NeuroMab™ Anti-CXCR4 BBB Shuttle Antibody(NRZP-1022-ZP3784)

Figure 1 shows the ADCC activity of 12A11, 6B6 and 3G10 anti-human CXCR4 antibodies on Ramos (NHL) cells.

Figure 2 shows the inhibition of calcium flux by 3G10, 6B6 and 12A11 anti-human CXCR4 antibodies.

Figure 3 shows that 3G10, 6B6 and 12A11 anti-human CXCR4 antibodies significantly inhibited tumor growth in a non-Hodgkin's lymphoma (NHL) model (Ramos) compared to an isotype control antibody.

Figure 4 shows that anti-human CXCR4 antibodies 3G10, 6B6 and 12A11 had a significant effect on tumor burden in animals systemically implanted with Raji-LUC cells compared to an isotype control antibody.

Figure 5 is a survival curve showing the significant effect of anti-human CXCR4 antibodies 3G10, 6B6 and 12A11 compared to an isotype control antibody on the survival of animals systemically implanted with Raji-LUC cells.

Figure 6 shows the significant antitumor effect of CXCR4 ADCs 3G10-TG6-vc0101 and 6B6-TG6-vc0101 in Ramos (NHL) tumor model.

Figure 7 shows the effect of CXCR4 Ab 6B6 on tumor burden in an acute myelogenous leukemia (AML) model (MV4-11-LUC). Representative bioluminescent imaging of 5 animals/treatment group from day 20 to day 41 is shown.

Figure 8 shows the significant effect of anti-CXCR4 antibody 6B6 on the survival of animals systemically implanted with MV4-11-LUC AML cells compared to an isotype control antibody.

Figure 9 shows that at day 35 of the study, human AML tumor burden was significantly reduced in the peripheral blood (PB) of animals treated with anti-CXCR4 6B6 antibodies compared to isotype control treated animals.

Figure 10 shows the CDC activity of 12A11, 6B6 and 3G10 anti-human CXCR4 antibodies on Ramos (NHL) cells.